Sepsis Clinical Trial
Official title:
SHOCK US STUDY: Fluid Responsiveness in Sepsis Measured by Ultrasonography
NCT number | NCT02170233 |
Other study ID # | 1406014123 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 2014 |
Est. completion date | June 2016 |
Verified date | January 2020 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The study aim is to examine point-of-care ultrasound findings, reliability, and ease of performance in association with fluid responsiveness for patients with severe sepsis and septic shock. The investigators propose a prospective observational research study of patients presenting to one of three Yale New Haven Hospital emergency departments, York Street Campus, St. Raphael's Campus, and Shoreline Medical Center who meet criteria for sepsis, severe sepsis or septic shock during their emergency department visit.
Status | Completed |
Enrollment | 65 |
Est. completion date | June 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - All patients age greater than 18 years who meet criteria of sepsis. Septic shock will be defined as those patients with severe sepsis and persistent hypotension (<90mmHg systolic blood pressure) despite a fluid challenge of at least 20cc/kg - Patients will only be considered eligible for enrollment if the treating physician plans to give at least 1-liter of crystalloid after initial US is performed - A number (approximately 50 patients) with no symptoms of sepsis will be enrolled to assess measurements in healthy patients. These patients will only have one ultrasound performed for each of the desired study measures. Exclusion Criteria: - Patients unable to provide consent such as non-English speaking patients or patient/health care proxy unable to give consent - History of significant trauma - Incarcerated patients - Failure to complete fluid challenge - Pericardial disease or heart transplant. Patients with left bundle branch block, pulmonary hypertension, known systolic dysfunction (Ejection Fraction <40%), receiving vasopressors, known moderate or severe valvular dysfunction, and irregular heart rhythms will be enrolled but analyzed separately |
Country | Name | City | State |
---|---|---|---|
United States | Yale University | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fluid responsiveness as defined by 15% increase in cardiac output in response to 1 liter of IV fluid | Ultrasound Measurement: Carotid corrected flow time in relation to cardiac output to assess fluid responsiveness. |
participants will be followed for the duration of their emergency department stay, an expected average of 6 hours | |
Secondary | Fluid volume measurement as measured by ultrasound | Ultrasound Measurement: IVC diameter in relation to cardiac output to assess fluid responsiveness. |
participants will be followed for the duration of their emergency department stay, an expected average of 6 hours | |
Secondary | Early (E') septal left ventricular filling velocity as measured by ultrasound | Ultrasound Measurement: Early (E') septal left ventricular filling velocity by tissue Doppler in relation to cardiac output to assess fluid responsiveness. |
participants will be followed for the duration of their emergency department stay, an expected average of 6 hours | |
Secondary | Late (A') septal left ventricular filling velocity as measured by ultrasound | Ultrasound Measure: Late (A') septal left ventricular filling velocity by Tissue Doppler in relation to cardiac output to assess fluid responsiveness. |
participants will be followed for the duration of their emergency department stay, an expected average of 6 hours | |
Secondary | Respirophasic carotid velocity (?Vpeak) as measured by ultrasound in relation to cardiac output to assess fluid responsiveness. | Ultrasound Measure: Respirophasic carotid velocity (?Vpeak) in relation to cardiac output to assess fluid responsiveness. |
participants will be followed for the duration of their emergency department stay, an expected average of 6 hours | |
Secondary | Early (E) mitral inflow velocity in relation to cardiac output to assess fluid responsiveness as measured by ultrasound. | Ultrasound Measurement: Early (E) mitral inflow velocity in relation to cardiac output to assess fluid responsiveness. |
participants will be followed for the duration of their emergency department stay, an expected average of 6 hours | |
Secondary | Late (A) mitral inflow velocity in relation to cardiac output to assess fluid responsiveness as measured by ultrasound. | Ultrasound Measurement: Late (A) mitral inflow velocity in relation to cardiac output to assess fluid responsiveness. |
participants will be followed for the duration of their emergency department stay, an expected average of 6 hours | |
Secondary | Carotid velocity-time integral in relation to cardiac output to assess fluid responsiveness as measured by ultrasound. | Ultrasound Measurement: Carotid velocity-time integral in relation to cardiac output to assess fluid responsiveness. |
participants will be followed for the duration of their emergency department stay, an expected average of 6 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |